Soleo Health Selected By Genentech To Provide Two Limited Distribution Drugs
Company’s Clinical Expertise, Positive Patient Outcomes Garners Access to Limited Drug Distribution
McKinney, Texas, June 27, 2018 – Soleo Health, an innovative leader in specialty infusion services, announced today the company has been selected by Genentech (member of the Roche Group), a world-leading biotechnology company with multiple products on the market and a strong development pipeline, to dispense two limited distribution drugs, Hemlibra® and Ocrevus®.
Hemlibra® (emicizumab-kxwh), for patients with hemophilia A with factor VIII inhibitors, received approval from the Food and Drug Administration (FDA) in November 2017. Ocrevus® (ocrelizumab) is used for patients with relapsing or primary progressive forms of multiple sclerosis and was approved by the FDA in March 2017. Soleo Health has extensive clinical experience in treating patients with these conditions. The company’s highly trained clinical team has engaged in comprehensive training and education for the delivery of these two medications.
As a leading specialty infusion services provider with licensure in 50 states, Soleo Health is quickly gaining expanded access to several limited drug distribution networks as it becomes increasingly recognized for its proven clinical track record, positive patient outcomes and expertise in caring for patients in the home or alternate site setting. Currently, Soleo Health administers the patient care services and delivery of nine limited distribution drugs across multiple therapeutic classes.
“The selection of Soleo Health by Genentech is demonstrative of our exceptional clinical experience and service capabilities. We are pleased to be chosen to administer these important life-changing therapies. Being part of manufacturer limited drug distribution networks expands Soleo Health’s clinical service offering for patients, providers and payors, and helps fuel our continued rapid growth. This is a testament to our reputation and commitment to providing outstanding patient care as well as our dedication to improving clinical outcomes,” explained Craig Vollmer, executive vice president at Soleo Health.
Contributing to Soleo Health’s participation in limited drug distribution opportunities is its innovative proprietary clinical outcomes program, SoleMetrics®, designed to provide customized outcome data for physicians, health systems, accountable care organizations, payors and manufacturers. Developed through years of clinical experience, along with input from leading healthcare professionals, SoleMetrics has fast-emerged a valuable resource used by Soleo Health clinicians to enhance the patient experience and improve clinical outcomes, leading to reductions in the total cost of care.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company is among the world’s leading biotech companies, with multiple products on the market and a promising development pipeline.
Hemlibra® (emicizumab-kxwh) is a registered trademark of Chugai Pharmaceutical Co., Ltd. and Ocrevus® (ocrelizumab) is a registered trademark of Genentech.
About Soleo Health
McKinney, Texas-based Soleo Health is an innovative national provider of specialty home and alternate-site infusion services. Its team of experienced clinicians provides exceptional clinical care and support in managing patients with complex or chronic conditions through comprehensive therapy management programs. Soleo’s patients’ clinical needs are met by its compassionate and caring associates who deliver personalized care.
Soleo Health operates 19 locations through the U.S. with pharmacy licensure in 50 states and is accredited by The Joint Commission. For more information, visit www.soleohealth.com or connect with Soleo Health on Facebook, Twitter and LinkedIn.